Organon & Co. (NYSE:OGN) Stock Now Rated “Reduce” by Sell-Side Brokerages

Shares of Organon & Co. (NYSE:OGN) have been assigned an average rating of “Reduce” from the seven ratings firms that are covering the company, MarketBeat Ratings reports. Two investment analysts have rated the stock with a sell rating and five have assigned a hold rating to the company. The average 1-year target price among analysts that have updated their coverage on the stock in the last year is $11.40.

Separately, Weiss Ratings raised shares of Organon & Co. from a “hold (c-)” rating to a “hold (c)” rating in a research report on Thursday.

Organon & Co. Stock Performance

Shares of NYSE OGN traded up $0.01 during trading hours on Tuesday, reaching $13.78. The stock had a trading volume of 702,842 shares, compared to its average volume of 5,195,578. The firm has a market cap of $3.62 billion, a price-to-earnings ratio of 17.89, a PEG ratio of 1.28 and a beta of 1.55. Organon & Co. has a fifty-two week low of $5.69 and a fifty-two week high of $13.83. The firm has a 50-day moving average of $13.71 and a 200-day moving average of $12.59. The company has a current ratio of 1.95, a quick ratio of 1.44 and a debt-to-equity ratio of 8.43.

Organon & Co. Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Thursday, September 10th. Shareholders of record on Friday, August 14th were given a dividend of $0.02 per share. The ex-dividend date was Friday, August 14th. This represents a $0.08 dividend on an annualized basis and a yield of 0.6%. Organon & Co.’s dividend payout ratio is presently 10.39%.

Institutional Trading of Organon & Co.

Hedge funds have recently modified their holdings of the business. Allied Private Wealth LLC acquired a new stake in Organon & Co. in the second quarter valued at $33,000. WNY Asset Management LLC purchased a new position in shares of Organon & Co. during the 1st quarter worth approximately $64,000. Wealth Effects LLC acquired a new position in shares of Organon & Co. in the first quarter worth $75,000. Nykredit A S purchased a new position in Organon & Co. in the 2nd quarter valued at about $76,000. Finally, GAMMA Investing LLC lifted its stake in shares of Organon & Co. by 69.8% during the second quarter. GAMMA Investing LLC now owns 5,782 shares of the company’s stock valued at $78,000 after buying an additional 2,376 shares during the period. 77.43% of the stock is owned by institutional investors and hedge funds.

Organon & Co. Company Profile

Organon & Co is a global healthcare company focused primarily on women’s health, biosimilars and a portfolio of established medicines. The company develops, manufactures and commercializes prescription products designed to address a range of health needs, with an emphasis on expanding access to treatments in markets around the world.

Its women’s health portfolio includes contraceptive products such as Nexplanon and NuvaRing, as well as medicines used in areas including fertility and reproductive health.